Figure 1 | Blood Cancer Journal

Figure 1

From: The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Figure 1

Pracinostat downregulates JAK and FLT3 signaling in JAK2V617F and FLT-ITD cell lines, and shows synergy in combination with pacritinib. (a–d) Western blot analyses from 25 or 50 μg (pFLT3 and FLT3 blots only) of total cell lysate of the indicated cell lines with JAK2V617F, JAK2, or FLT3-ITD or FLT3 wt are shown. (a, b) Cells were treated with the indicated concentrations of pracinostat (SB939) for 24 h. (c, d) Cells were treated for 24 h with pracinostat with pacritinib (SB1518) added in the indicated concentrations for the last 2 h of incubation before lysis.

Back to article page